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Glycoprotein B (gB, gpUL55) is a major antigen for the induction of neutralizing antibodies against human cytomegalovirus,
making it an attractive antigen for active and passive immunoprophylaxis. The immunodominant region on gB is the antigenic
domain 1 (AD-1), a complex structure which requires a minimal linear amino acid sequence of more than 75 amino acids
(aa 552–635) for antibody binding. We have analyzed the fine specificity of neutralizing and nonneutralizing AD-1-binding
monoclonal antibodies. Point mutations were introduced into AD-1 and mutants were expressed as bacterial fusion proteins.
The antigens were analyzed in immunoblots using a panel of 13 human and murine monoclonal antibodies. Complete loss
of binding of all antibodies was observed with mutations at cysteine residues 573 and 610 as well as with a combinatorial
exchange of prolines at position 577 and 613. The remaining mutations had different effects on antibody binding. Six
individual recognition patterns were observed, indicating various antigenic substructures on AD-1. Changing the Fc portions
of 3 murine monoclonal antibodies to human IgG1 showed that neutralization of AD-1-binding immunoglobulins is exerted
by different mechanisms. Dependent on the recognized substructure within AD-1, avidity-dependent as well as Fc portion-
mediated effects were observed. q 1996 Academic Press, Inc.
INTRODUCTION immunoglobulin preparations are derived from a pool of
different individual donors.
Infections with human cytomegalovirus (HCMV) con-
Glycoprotein B (gB) is the dominant antigen on the
tinue to be an important clinical problem in certain pa-
envelope of HCMV and nearly 100% of HCMV-infected
tient populations. The virus remains a major cause of individuals develop antibodies against this protein
morbidity and mortality in immunocompromised hosts, (Kniess et al., 1991; Marshall et al., 1992). Antibody pread-
such as transplant recipients and patients with AIDS. sorption experiments with recombinant-derived gB have
Both cellular and humoral immune responses are likely shown that in some human sera a considerable fraction
to be involved in the restriction of HCMV infections. In of the neutralizing response is directed against gB (Britt
several previous studies passive transfer of immunoglob- et al., 1990; Marshall et al., 1992). Consequently gB has
ulins has been shown to modulate serious HCMV dis- been proposed as a candidate for a subunit vaccine,
ease by limiting virus dissemination, possibly by provid- and protein purified from virus preparations, as well as
ing neutralizing antibodies (for review see Zaia, 1993). recombinant gB, has been used in first vaccination stud-
Also, in a recent vaccination trial, protection from reinfec- ies (Gonczol et al., 1991; Pass et al., personal communi-
tion was found to correlate with neutralizing antibodies cation). The majority of gB-specific antibodies which are
(Adler et al., 1995). In the closely related murine cytomeg- developed during natural infection are directed against
alovirus system antibodies can limit dissemination of re- the antigenic domain 1 (AD-1). During natural infection
current virus and also provide protection from a lethal and after immunization in mice, AD-1 is capable of induc-
challenge (Jonjic et al., 1994, Rapp et al., 1993). However, ing neutralizing and competing nonneutralizing antibod-
the results from clinical studies remain controversial (for ies in a single individual, a fact which could complicate
review see Zaia, 1993). A significant problem in the inter- its inclusion in a subunit vaccine or its use as target
pretation of these clinical trials has been the use of a antigen for selection of neutralizing human monoclonal
number of different immunoglobulin preparations, all of antibodies (Ohlin et al., 1993; Utz et al., 1989). In addition,
which could be expected to vary in their titer of HCMV- AD-1 is an unusual complex structural domain. Although
specific antibodies (Chehimi et al., 1987; Schmitz and antibody binding takes place under denaturing condi-
Essuman, 1986). This problem will remain as long as tions, a minimum of more than 75 residues of continuous
primary amino acid sequence between amino acids (aa)
552 and 635 is essential for reactivity (Wagner et al.,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: -9131 852101. 1992). Using amino acid deletions from the amino- or
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TABLE 1carboxyterminal boundary of AD-1, we were not able to
establish substructures or to differentiate individual bind- Characteristics of AD-1-Specific Murine
ing patterns for neutralizing or nonneutralizing human and Human Monoclonal Antibodies
and mouse antibodies. Likewise attempts to define sub-
Virusunits of AD-1 using synthetic peptides of various length
Monoclonal Recognitionhave been unsuccessful (Wagner et al., 1992). These
antibody subgroup Isotype Neutralization Avidity indexa
results raised the question whether AD-1 as a structure
is inducing only a single type of antibody with the differ- 27-156 A IgG2b/k Yesb 0.88
27-78 A NDc Yes 0.88ences in biological activity being due to events second-
27-83 A ND Yes 0.87ary to AD-1 binding or whether AD-1 contains substruc-
ITC63B A IgG1/l Yesd 0.86tures which can induce neutralizing or nonneutralizing
ITC52 A IgG1/k Yes 0.74
antibodies. ITC39e A IgG1/l No 0.02
In this investigation we have further analyzed the fine 28-287 B IgG2b/k Yes 0.87
ITC33 B IgG1/l No 0.65specificity of AD-1-binding monoclonal antibodies. Our
7-17 C IgG3/k Yes 0.45data indicate that AD-1 contains various substructures
7-5 C IgG1 No 0.06to which antibodies can bind. When Fc portions of AD-
9-3 D IgG2a Yes 0.14
1-binding antibodies were changed from murine to hu- ITC48 E IgG1/k Yes 0.44
man, a significant increase in neutralization capacity was 27-11 F ND No 0.41
noted for one antibody, suggesting a participation of the
a Avidity index was performed as described under Materials andFc portion in the neutralization mechanism of AD-1-spe-
Methods and calculated according to the formula (OD value samplecific antibodies.
plus 7 M urea/OD value sample without urea).
b Neutralization capacity of murine mabs established in this study
MATERIALS AND METHODS according to the procedures described under Materials and Methods.
c Not determined.
Cells and viruses d Neutralization capacity of ITC series according to Ohlin et al., 1993.
e Nonneutralizing antibodies are shown in bold.Human foreskin fibroblasts were grown in minimal es-
sential medium (Gibco BRL, Glasgow, Scotland) supple-
WI). All primers were provided by the kit and the manufac-mented with 5% fetal calf serum (FCS), glutamine (100
turer’s instructions were followed precisely. The mRNAmg/liter), and gentamycin (350 mg/liter). Propagation and
coding for the variable light chain of the antibody 7-17gradient purification of HCMV strain AD169 was carried
could not be amplified by this procedure. Therefore a G-out by the method of Talbot and Almeida (1977).
tailing reaction of the reverse-transcribed cDNA of hy-
bridoma 7-17 was performed as described by Saiki et al.Monoclonal antibodies and bacterial fusion proteins
(1988), followed by PCR amplification. Two 5*-primers (G-
Hybridoma cell lines were propagated in RPMI 1640 tailing 1, G-tailing 2) as well as one 3*-primer (G-tailing)
(Gibco BRL) supplemented with 10% FCS, glutamine, and were used simultaneously (Table 2). The aberrant chains
gentamycin. Antibodies were purified from tissue culture secreted by the myeloma fusion partner P3X63–Ag8.653
supernatant by ammonium sulfate precipitation or on and Vl of the antibody 7-17 were amplified by this proce-
protein G–Superose columns (Pharmacia, Freiburg, Ger- dure (Carroll et al., 1988). The PCR products were directly
many) (Harlow and Lane, 1988). Specifications of AD-1- cloned into the vector pT7Blue (Ig-Prime kit) and used
binding antibodies are shown in Table 1. The Exo-pro- to transform bacterial strain Nova Blue (Ig-Prime kit) by
teins contained the following amino acids of gB as trpE electroporation. Bacterial colonies containing the aber-
fusion proteins: Exo 58-314 (aa 549–636), Exo 58-315 (aa rant k-light chain were identified by hybridization using
549–635), Exo 58-310 (aa 549–632), Exo 58-36 (aa 549– a specific oligonucleotide (5*-CACATTAGGGAGCTTACA-
630), Exo 58-35 (aa 549 –628), Exo 58-5A15 (aa 552 – CGT3*) for the aberrant chain. The DNA of clones which
653), Exo 58-5E1 (aa 556–653), Exo 58-5E8 (aa 557 – showed no signal in the colony hybridization was se-
653), Exo 58-D7 (aa 561–635), and Exo 58-5E39 (aa 564 – quenced. All working procedures were performed ac-
635) (Wagner et al., 1992). cording to Sambrook et al. (1989).
The following accession numbers were assigned:
PCR amplification and cloning of variable light (Vl) U39898 to sequence 7-17Vh of antibody 7-17, U39899 to
and variable heavy (Vh) coding sequences 27-156Vh, U39900 to 27-287Vh, U39901 to 7-17Vl, U39902
to 27-156Vl, U39903 to 27-287Vl.Total RNA was prepared from 2 1 107 cells according
to Chomczynski and Sacchi (1987). Reverse transcription
Chimerization of antibodies 7-17, 27-156, and 27-287and PCR amplification of the mRNAs coding for variable
regions of the antibodies 7-17, 27-156, and 27-287 were DNA from clones containing Vh or Vl sequences was
PCR-amplified from the respective plasmid using thecarried out by using the Ig-Prime kit (Novagen, Madison,
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TABLE 2
Sequences of Primers Used for G-Tailing Reaction and Cloning of Vl/Vh into the Vectors pUHWk and pUHWg
Primer Sequence
5* primer G-tailing (1) 5*-CGTAGAATTCGCTGCAACCGTGCCCCCCCCCCCC3*
5* primer G-tailing (2) 5*-CGTAGAATTCGCTGCAACCGTG3*
3* primer G-tailing 5*-GGAAGCTTACTGGATGGTGGGAAGATGGA3*
5* primer 7-17 Vl 5* GATCGTCGACATGAAGTTGCCTGTTAGGC3*
5* primer 27-156 Vl 5* GATCGTCGACATGGAGACAGACACACTCC3*
5* primer 27-287 Vl 5* GATCGTCGACATGGAGACAGACACACTCC3*
3* primer k 5*-GAGCGCGGCCGCACTTACGTTTTATTTCCAGCTTGG3*
5* primer 7-17 Vh 5* CATAGTCGACATGAAATGGAGCTGGGTC3*
5* primer 27-156 Vh 5* CATAGTCGACATGGAATGGACCTGGGTC3*
5* primer 27-287 Vh 5* CATAGTCGACATGGAATGCAGCTGGGTC3*
3* primer g1 5* GAGCGCGGCCGCACTTACCTGAGGAGACGGTGAC3*
primers shown in Table 2 and inserted into the vectors transfected into Escherichia coli C600 and DNA se-
quence analysis of all plasmids was performed to con-pUHWk and pUHWg, respectively (Weissenhorn et al.,
1991). All 3*-primers contained a splice donor site 5*ACT- firm single point mutations within AD-1.
TAC3*, since plasmids pUHWk and pUHWg were origi-
nally constructed for the expression of genomic variable Evaluation of antibody fine specificity
region sequences and contain the respective splice ac-
Preparation of bacterial fusion proteins, as well asceptor site at the 5*-end of the constant coding region.
immunoblot analysis, was performed as described byVectors were linearized at their unique PvuI sites before
Wagner et al. (1992) with the exception that in sometransfection into hybridoma cell lines SP2/O and CB-F7
assays antibody binding was detected with an enhanced(Charite´, Berlin, Germany) (Grunow et al., 1988). To gen-
chemoluminescence Western blotting system (ECL; Am-erate stable transformants with a high frequency the
ersham International, UK). ELISAs using AD-1 sequenceselectroporation conditions were optimized for each DNA
as antigen were performed as described by Wagner etpreparation. In general, 5 1 106 cells were mixed with
al. (1992). Neutralization assays were carried out as de-15 mg linearized DNA in 0.8 ml HEPES buffer. Usually
scribed by Andreoni et al. (1989) with slight modifications.electroporation conditions of 960 mF, 9–11 ms, and 280 –
Various amounts of virus and antibody were preincu-340 V produced more than 50% mortality of cells and
bated in 100 ml RPMI 1640 for 4 hr at 377. Human fibro-stable transfectants could be generated. Transfected
blasts (3 1 104) were added in a volume of 25 ml mediumcells were propagated in 96-well round-bottom plates.
and the mixture was seeded in 1 well of a 96-well plate.Stable clones were isolated by G418 selection (1 mg/
After infection for 20 hr at 377, cells were fixed with abso-ml) added 24 hr after electroporation. Chimeric antibody-
lute ethanol and stained with a monoclonal antibodyproducing cells were detected by a capture ELISA. The
(P63-27) reactive with the major immediate-early proteinmouse monoclonal antibody anti-human IgG1 (Dako, Bre-
of HCMV (UL123). Antibody binding was detected by amen, Germany) was diluted to 1.5 mg/ml in 0.05 M car-
fluorescein-conjugated anti-mouse antibody. Generally,bonate buffer, pH 9.5, and used to coat microtiter plates
infectious doses were adjusted to 150 infected cellsfor 16 hr at 47 in a humid chamber. Supernatant from
counted on a fluorescence microscope (Zeiss/Axioskoptransfected cells was added (50 ml/well) and after 2 hr
MC80) using a 2001 magnification. To enable the com-of incubation at 377 a peroxidase-conjugated mouse
parison of murine and chimeric antibodies with respectmonoclonal antibody directed against human k chains
to neutralizing capacity, two approaches were followed.(Dako) was used to detect correctly assembled antibod-
The protein concentration of each antibody preparationies. Cells producing intact antibody molecules were re-
was measured with a BCA Protein Reagent Assaypeatedly subcloned and expanded.
(Pierce, Rockford, IL) and the relative amount of AD-1
binding antibodies was determined in an ELISA usingSite-directed in vitro mutagenesis of the AD-1 coding
AD-1 as antigen. To minimize the effect of potentiallysequences
different avidities of anti-human and anti-mouse peroxi-
dase-coupled antibodies, we used polyclonal immuno-Starting with the construct Exo 58-315 which ex-
presses aa 549–635 of HCMV gB as trpE fusion protein globulins as a detection system. Neutralization capacity
of each given antibody preparation was normalized in(Wagner et al., 1992), point mutations were introduced
into AD-1 according to Dulau et al. (1989) using PCR the AD-1 ELISA (A490nm) and the corresponding protein
concentration was calculated. Two murine monoclonalamplification with degenerate primers. Mutant DNA was
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antibodies, 3H82 and E6H6 (anti-b-galactosidase and monoclonal antibodies 27-156 and 7-17 are shown in Fig.
1. Qualitative differences in binding to individual fusionanti-tryptophan synthetase), were used as a control. The
standard error of the assay was in the range of 10%. proteins were observed for all mabs. These differences
were reproducible in repeated analyses. In all immu-To determine antibody avidity, the standard ELISA was
modified. After formation of the antibody–antigen com- noblots great care was taken to apply equal amounts of
fusion proteins to the analysis, and controls included theplex, wells were treated for 4 min with PBS containing
various concentrations of urea (5–7 M). Plates were AD-1-specific murine monoclonal antibody B1B6 which
was reactive with all fusion proteins (see Fig. 2). Thewashed three times (5 min each) with PBS–0.05% Tween
20 and anti-mouse or anti-human antiserum coupled to data for all mabs are summarized in Table 3. Six different
binding patterns were observed (Groups A–F, Table 3).horseradish peroxidase was added. Alternatively, anti-
body–antigen complexes were treated with PBS–6 M Mutations involving cysteine residues at positions 573
or 610 or combinatorial exchange of prolines 570/577urea for various times (1 –7 min). The avidity index for
each monoclonal antibody was calculated according to as well as 577/613 resulted in loss of binding for all
antibodies. For the reason mentioned above the weakthe formula (OD value sample plus urea/OD value sam-
ple without urea). Comparative analyses were performed reactivity of antibody 7-17 with lower molecular weight
proteins in the proline 570/613 mutant represented non-by testing all antibodies simultaneously on the same
ELISA plate since the incubation time of preformed anti- specific signals. The remaining mutations had different
effects on antibody binding. From these data it must bebody–antigen complexes with different concentrations
of urea was critical for the avidity index. concluded that a number of antigenic substructures exist
on AD-1 against which antibodies are formed after natu-
ral infection or immunization. However, as in our previousRESULTS
analyses, we were unable to establish a correlation be-
Monoclonal antibodies define antigenic substructures
tween specificity of a particular antibody and neutralizing
within antigenic domain AD-1
capacity. Within group A, for example, one nonneutraliz-
ing antibody (ITC39) as well as five neutralizing antibod-AD-1 is a complex antigenic domain which has been
characterized in detail in previous investigations (Wagner ies (ITC52, ITC63B, 27-156, 27-83, 27-78) were found.
Similarly, groups B and C contained neutralizing and non-et al., 1992; Utz et al., 1989; Ohlin et al., 1993). The binding
of antibodies to this domain was analyzed with a panel of neutralizing antibodies.
bacterial fusion proteins expressing sequences between Avidity of AD-1-specific antibodies
residues 549 and 645 of gB. These previous studies have
In the next series of experiments we determined thesuggested that a linear sequence of the AD-1 antigenic
avidity of AD-1-specific antibodies in order to evaluatesite was recognized as a single epitope by AD-1-specific
potential correlation between antibody reactivity andneutralizing and nonneutralizing monoclonal antibodies
neutralization capacity. An ELISA was developed in(mabs). Amino acid insertions as well as carboxy- or
which the preformed antibody–antigen complex wasaminoterminal deletions abrogated mab reactivity, sug-
treated with different concentrations of urea and residualgesting this region exhibited a unique conformation,
bound antibody was expressed as function of urea con-which was dependent on an intact primary sequence.
centration. The results were expressed as relative avidityHowever, competition experiments also suggested that
index as described under Materials and Methods. Whendifferent antibody binding structures might exist on AD-1.
antibodies within one species were compared, avidityIn the present study an attempt was made to differentiate
was not correlated to neutralizing activity (Table 1). Thisthese specificities by mutating single amino acids in AD-
was illustrated for example by the lower avidity index of1. Amino acids were selected for mutation based on
the neutralizing murine antibody 9-3 compared to thecomputer predictions which indicated contribution of the
nonneutralizing antibody 27-11A. Likewise, the humanresidues to secondary structure. In particular the proline
antibody ITC33, which is nonneutralizing, had a higherresidues at positions 570, 577, and 613, as well as the
avidity index than ITC48, which is neutralizing. Interest-serine residues at positions 586 and 587, were mutated.
ingly, within antibodies from one subgroup increasingIn addition, the cysteine residues which are present in
avidity to AD-1 was correlated to neutralizing activity,AD-1 at positions 573 and 610 and which potentially
suggesting that avidity might be important for neutralizing
could form disulfide bonds were altered to serine. The
activity in those cases where similar substructures on
mutated fusion proteins were analyzed in immunoblots
AD-1 are recognized.
with eight mouse and five human AD-1-specific mabs. In
Synthesis of chimeric antibodies having human Fceach group two of the antibodies have been shown to
and murine Fv regions and analysis of bindinglack virus neutralizing activity (Table 1). Using this ap-
specificitiesproach it was possible to discriminate binding specifici-
ties between antibodies. As an example, the individual In attempting to establish correlations between avidity
and neutralizing activity, we did not differentiate betweenbinding patterns that were observed for the murine
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FIG. 1. (A) Reactivity of murine monoclonal antibodies for bacterial fusion proteins containing mutations in AD-1. E. coli lysates containing the
indicated fusion proteins were separated on SDS–PAGE and transferred to nitrocellulose membranes. After blocking, individual blots were incubated
with monoclonal antibodies 27-156 and 7-17, respectively. Bound antibody was detected with alkaline phosphatase-conjugated anti-mouse IgG and
developed with the ECL chemoluminescence system (Amersham). The position of the molecular mass standard (in kilodaltons) is indicated. Fusion
proteins were designated according to the amino acid that was changed within AD-1, i.e., Cys 573 represents an AD-1 mutant with a replacement
of cysteine at position 573. Double mutants were designated accordingly. pATH and Exo 58-315 represent control antigens containing the fusion
partner trpE and AD-1 (aa 549 – 635), respectively. (B) Schematic diagram depicting location of AD-1 relative to gB and mutations within AD-1. At
the top full-length gB is shown with AD-1 indicated by the shaded box. Membrane anchor (dark box) and proteolytic cleavage site (arrow) are also
indicated. The AD-1 mutants are shown on an expanded scale. Residues inside the bar represent the original AD169 gB sequence. The mutated
amino acids are shown below the bar. Numbers refer to amino acid position within gB.
human and mouse monoclonal antibodies. The validity mined. During the process of constructing the chimeric
antibodies we noted several features of the murine antibod-of this interpretation can be questioned, since it has been
shown that the Fc portion, which is different between ies 7-17, 27-156, and 27-287. The most relevant characteris-
tics are summarized in Fig. 3 and Table 4 and included:human and mouse IgG, has a potential influence on anti-
body avidity and hence on neutralization capacity (More-
(i) the Vl chains originated from different Vk genelock et al., 1994; Cooper et al., 1991; Bruggemann et al.,
groups and showed between 73 and 77% homology on1987; Persson et al., 1988). However, the limited number
the nucleotide level and 54 and 59% on the amino acidof available AD-1-specific antibodies did not allow a sep-
level (data not shown);arate evaluation of the two species. We addressed this
(ii) Vh chains had similarities between 86 and 92%problem by providing the human constant region g1 to
(nucleotide level) and 67 and 85% (amino acid level) andthree murine monoclonal antibodies (27-156, 27-287, and
could be assigned to the J558 family. However, the Vh7-17), thereby generating antibodies with identical hu-
chain of antibody 7-17 was derived from a different geneman Fc portions in groups A and B and with different Fc
segment from that of the other two murine antibodies;portions in group C. In addition, mab 7-17 was the only
(iii) the length of the third hypervariable region of themurine antibody with an IgG3 constant region which
heavy chain (CDR3), which for most antibodies is crucialcould mediate biological activity via cooperativity through
for contact to the antigen, varied from 10 to 15 aminoFc–Fc interactions (Fulpius et al., 1993; Greenspan and
acids, indicating independent recombination events. NoCooper, 1993; Cooper et al., 1991). Sequence information
apparent requirement for particular amino acid residuesof these antibodies would also provide information on
at any position of this region was found. The third hyper-the degree of diversity between AD-1-specific antibodies.
variable region CDR3 is generated by Vh–Dh–Jh joining.We generated human–mouse chimeric antibodies by
Random nucleotide addition (N regions) and junctionalfirst isolating mRNA from the respective hybridomas. After
flexibility makes assignment of the Dh origin problematic.reverse transcription of mRNA to cDNA, coding sequences
for the Vh and Vl chains were amplified by PCR and inserted The D segment of antibody 7-17 showed highest homol-
ogy to the DSP 2-4 element and was flanked on bothinto plasmids and the nucleotide sequence was deter-
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FIG. 2. Reactivity of murine (27-287 murine) and chimeric (27-287 human) monoclonal antibodies with AD-1-containing bacterial fusion proteins.
Immunoblot analyses were performed as described in legend to Fig. 1. The position of the molecular mass standard (in kilodaltons) is indicated.
For specification of the bacterial fusion proteins see Fig. 1A and Material and Methods. The murine monoclonal antibody B1B6, reactive with all
AD-1-containing fusion proteins, was used as control.
sites by N regions. For the other two antibodies no clear that were observed in repeated analyses showed no quali-
tative differences between murine and chimeric antibod-homology to any of the known murine D segments could
be established. However, both antibodies most probably ies when fusion proteins from mutated and nonmutated
AD-1 sequences were used as antigen. As an examplecontain D–D segment fusions which have occasionally
been observed (Meek et al., 1989). From these data it the results obtained with murine and chimeric antibody
27-287 are shown (Fig. 2). Again, the difference in signalmust be concluded that a significant degree of structural
diversity exists among murine mabs that share specificity strength that was seen between the fusion proteins was
not due to varying amounts of antigen present on thefor the same antigenic determinant on gB. These findings
were consistent with the antigenic specificities of the nitrocellulose filters as shown by control antibody B1B6
(Fig. 2). Reactivity of the respective mouse and chimericantibodies.
antibody pairs was determined on the same nitrocellulose
The chimeric antibodies were constructed by combin-
filter with stripping of the first antibody followed by binding
ing the Fv coding sequences of the AD-1-specific murine
of the second antibody to the same filter. There was no
antibodies with the constant regions of human immuno-
difference in reactivity with antibodies derived from SP2/
globulin g1 heavy chain and the k light chain. The re-
O and CB-F7 cells (data not shown).
sulting antibodies were designated 27-287hu, 27-156hu,
and 7-17hu, respectively. To exclude the possibility that Analysis of binding avidity and neutralizing activity of
chimerization had changed the specificity of the antibod- murine and chimeric antibodies
ies we compared reactivity of murine and chimeric anti-
body pairs with a panel of fusion proteins expressing se- We further characterized the chimeric antibodies by
comparing their relative binding avidities to AD-1 withquences from AD-1 in immunoblots. In addition to the AD-
1 mutant fusion proteins a set of previously described their respective parental murine antibodies. All three im-
munoglobulins showed changes in avidity after chimeri-polypeptides (the Exo-series; see Materials and Methods)
was used which contained amino- and carboxyterminal zation. At concentrations of 7 M urea the avidity index of
antibody 7-17hu increased from 0.45 to 0.77 (Fig. 4B). Indeletions of AD-1 (Wagner et al., 1992). Reaction patterns
/ 6a0f$$7677 01-04-96 11:43:58 vira AP-Virology
139ANTIBODIES SPECIFIC FOR AD-1 OF HUMAN CYTOMEGALOVIRUS
TABLE 3
Recognition Patterns of Murine and Human Monoclonal Antibodies with Different AD-1 Mutants
Recognition patterns of AD-1-specific antibodies
Fusion proteins
containing AD-1 A B C D E F
Exo 58-315 / / / / / /
C573 (rS)a 0 0 0 0 0 0
C610 (rS) 0 0 0 0 0 0
P570 (rA) / / / / 0 /
P577 (rA) 0 0 0 / 0 0
P613 (rA) / / 0 0 0 /
P570/P577 0 0 0 0 0 0
P570/P613 / 0 0 0 0 /
P577/P613 0 0 0 0 0 0
S586 (rI) / / / / / 0
S587 (rA) / / / / / /
27-156 27-287 7-17 9-3 ITC48 27-11b
27-83 ITC33 7-5
27-78
ITC39
ITC52
ITC63B
a Amino acid exchange produced by site-directed mutagenesis.
b Nonneutralizing antibodies are shown in bold.
contrast, the avidity indices for antibodies 27-287hu and preparations as well as of the antibody concentration
used in the assays (Fig. 4D). The changes in relative27-156hu decreased from 0.87 to 0.22 and 0.88 to 0.47,
respectively (Figs. 4A and 4C). Identical changes in avid- binding avidities of antibodies 27-287 and 27-156 com-
pared to antibody 7-17 were unexpected. However, theseity were seen when antigen–antibody complexes were
treated with 6 M urea for various times (data not shown). antibodies now provided a test panel for the hypothesis
that neutralizing activity within one AD-1-binding anti-The observed effect was independent of the antibody
FIG. 3. Deduced amino acid sequences of the Vh chains of murine antibodies 7-17, 27-156, and 27-287. Sequences of antibodies 27-156 and 27-287
were compared to 7-17. Identity with 7-17 is indicated by dashes and differences are displayed. Gaps have been introduced to facilitate alignment of
sequences and are marked by dots. Functional domains of the antibodies were identified according to Kabat et al. (1991) and are indicated.
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TABLE 4
Characteristics of Anti-AD-1 Murine Monoclonal Antibodies
V gene expression
Antibody Vl Jl Vh D Jh
7-17 V-kI/1A J2 J558/VH-IIb DSP2-4 J1
27-156 V-kII/V8 J2 J558/VH-I ?a J4
27-287 V-kIII/V21E J2 J558/VH-I ? J4
a Antibodies 27-156 and 27-287 possibly contain D–D fusions.
body subgroup was correlated with avidity. Since neutral- observed effects were independent of a number of pa-
rameters such as the cell line from which the chimericization is critically dependent on the actual concentration
of functional antigen-binding molecules in the respective antibodies were derived (CB-F7 or SP2/O) or the purifica-
tion procedure used (untreated tissue culture superna-preparations, we first carried out titrations of the respec-
tive antibody preparations in ELISAs using AD-1 as anti- tant, purification via protein G chromatography, or ammo-
nium sulfate precipitation) (data not shown). No differ-genic substrate. This allowed us to express the neutraliz-
ing activity of an individual antibody as a function of ences were seen with the chimeric antibodies 7-17hu
and 27-156hu, respectively, compared to their murineAD-1-binding activity. This approach gave reproducible
results when two different preparations of the same im- counterparts. As an example, data for 7-17 and 7-17hu
are shown in Fig. 5. Murine antibody 7-17 reduced inputmunoglobulin were compared (Fig. 4D). This was not the
case when comparative analyses where performed on infectivity by 73% at the maximum concentration of anti-
body in the assay, which is comparable to previous stud-the basis of protein concentrations (data not shown).
Neutralization assays were carried out at least two times ies (Britt, 1984). The most surprising finding was the
markedly increased activity of the 27-287 chimera. Thewith differences between assays of less than 10%. The
FIG. 4. Avidity determination of murine monoclonal antibodies and their chimeric counterparts. Determination of the individual avidity indices
was performed as described in legend to Fig. 2. (A–C) Murine–chimeric pairs. (D) Two different preparations of antibody 7-17 at different concentra-
tions [antibody 7-17(1), A490nm  3.579 at 0 M urea; antibody 7-17(2), A490nm  2.715].
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FIG. 5. Neutralization of HCMV by murine antibodies 27-287 and 7-17 and their chimeric counterparts. Neutralization analysis was performed as
described under Materials and Methods. Percentage of reduction of input infectivity was plotted as a function of AD-1-binding antibody concentration.
The relative concentration of AD-1-binding antibodies in individual preparations was determined in an ELISA assay using AD-1 as antigen. Absolute
amount of antibody at the highest concentration corresponded to 5.2 mg/ml for 27-287hu, 28.3 mg/ml for 27-287m, 8 mg/ml for 7-17hu, and 27.3 mg/
ml for 7-17m.
murine antibody 27-287 had a maximal neutralization ca- (i) AD-1 contains antigenic substructures which can
be defined by anti-AD-1 antibodies. Antibodies for whichpacity of 45%. However, the chimeric molecule almost
completely reduced infectivity of virus and reached neu- competition for binding to AD-1 has been shown in previ-
ous investigations did not fall into single subgroupstralization levels of 95% (Fig. 5). The difference between
27-287 and 27-287hu was also observed in assays where (Wagner et al., 1992; Utz et al., 1989; Ohlin et al., 1993).
(ii) The nature of the Fc portion of AD-1-binding anti-the number of infectious virus particles was titrated
against a constant concentration of antibody (data not bodies contributes to virus neutralizing activity.
shown). Tissue culture supernatants of murine mono-
The fact that monoclonal antibodies exhibited individ-clonal antibodies reacting with b-galactosidase or trypto-
ual binding specificities indicated recognition of differentphan synthetase did not reduce input infectivity.
antigenic substructures on AD-1. Even with our limited
set of AD-1 mutant fusion proteins we were able to differ-DISCUSSION
entiate six antibody binding patterns suggesting the exis-
tence of at least as many different antigenic substruc-Glycoprotein B is an important antigen for the induction
tures. This likely represents the lower estimate of theof neutralizing antibodies against HCMV. This makes gB
total number of antibody binding substructures on AD-1an attractive antigen for strategies of active and passive
since the mutations that were introduced most probablyimmunoprophylaxis (Azuma et al., 1991; Plotkin, 1991;
had a rather profound impact on AD-1 structure. ThisStarr et al., 1991; Aulitzky et al., 1991; Werner et al., 1993;
might have resulted in assignment of antibodies to oneSnydman, 1990). AD-1 represents the dominant antigenic
group which, upon a more refined analysis using addi-structure for induction of antibodies against gB. One hun-
tional mutant fusion proteins, could be differentiated withdred percent of infected individuals who are seropositive
respect to AD-1 recognition. Moreover, the limited num-for gB have antibodies against AD-1 (Kniess et al., 1991).
ber of available AD-1-specific antibodies represented anThe domain has been characterized in previous work
additional restriction in our analysis.and was shown to consist of a minimal linear amino acid
The complete loss of antibody binding with the cys-sequence of more than 75 amino acids between residues
teine mutant proteins indicated that these residues are552 and 635 of gB (Wagner et al., 1992). Binding of differ-
crucial for the formation of the antigenic structure AD-1.ent neutralizing and nonneutralizing murine and human
There are two possible ways in which the cysteine resi-monoclonal antibodies to this domain is competitive (Utz
dues could be involved in the architecture of AD-1: (i)et al., 1989; Ohlin et al., 1993).
formation of a disulfide bond between Cys573 andThe present study was undertaken to obtain more in-
Cys610 thereby creating a loop structure and (ii) forma-formation on the complex interaction of AD-1 with anti-
bodies. Two major conclusions can be drawn: tion of oligomers via disulfide bonds between different
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AD-1 molecules. Oligomerization of HCMV-gB via disul- original neutralization mechanism, probably mediated
through the Fab part of the antibody, an increased neu-fide bonds is well documented but the specific cysteine
residues responsible for these interactions have not tralization activity could occur. Steric effects that influ-
ence neutralization of viruses have been observed in abeen identified (Britt and Vugler, 1992). The fact that the
antibody binding form of AD-1 was observed at an appar- number of different systems (Possee et al., 1982; Taylor
et al., 1987; Taylor and Dimmock, 1985).ent molecular mass equivalent to the monomers does
not necessarily argue against this possibility since the
oligomers could form during the blotting procedure. For- Segment flexibility
mation of disulfide bonds at late stages in the analysis
has to be postulated for both models since fusion pro- Segmental flexibility of IgG molecules is a well-known
phenomenon and potentially facilitates bivalent antigenteins were reduced and denatured prior to analysis. How-
ever, our results do not rule out the possibility that forma- binding. The order of segmental flexibility has been
shown to be IgG2b  IgG2a  IgG3  IgG1 for mousetion of AD-1 is independent of the formation of disulfide
bonds. Reactivity with antibodies was also abrogated by antibodies and IgG3  IgG1  IgG4  IgG2 for human
immunoglobulins with the range of mobility remarkablymutations other than cysteine. Whether these modifica-
tions influenced formation of AD-1 structure independent similar in both species (Dangl et al., 1988; Gorman and
Clark, 1990). On the other hand, glycoproteins on theof disulfide bonds, prohibited correct formation of disul-
fide bonds, or altered the structure of AD-1 in the pres- surface of virions can adopt different conformations re-
sulting in the formation of a limited number of neutraliza-ence of correct disulfide bonds cannot be determined
from our analysis. No matter what the underlying mecha- tion-sensitive sites (Roben et al., 1994; Taylor et al., 1987;
Taylor and Dimmock, 1985; Dimmock, 1987). Increasednism for the differential antibody recognition, it must be
concluded that a variety of nonrelated antibodies having segmental flexibility of 27-287hu could therefore result in
an enhanced bivalent binding to neutralization-sensitivedifferent biological activities are induced by AD-1.
The second major conclusion from our study concerns sites. In this context it is worth mentioning that AD-1-
specific IgG molecules that are produced during naturalthe mechanisms of neutralization exerted by AD-1-spe-
cific antibodies. Neutralization of viruses can be infection exclusively belong to subclass 1, which is in
contrast to other glycoproteins of HCMV such as gH,achieved by a variety of mechanisms which in some
cases can operate simultaneously, even with monoclonal where IgG1 and IgG3 can be detected (Urban et al.,
1994). If segmental flexibility is critical for efficient neu-IgG (for a review see Dimmock, 1987). In most cases the
exact mechanism by which an antibody is exerting its tralization of HCMV in vivo, anti-AD-1 antibody responses
restricted to the IgG1 subclass may provide a mechanismneutralizing activity is not known. This is also true for
AD-1-binding antibodies. Given the individual recognition favoring persistence of HCMV.
Data in the literature on correlation of antibody aviditypatterns of the antibodies it is conceivable that they neu-
tralize through independent mechanisms. For antibodies and neutralizing capacity are conflicting. While some
studies did observe a positive correlation, others did notof the 27-156 and 7-17 type the Fc portion of the molecule
seems to be irrelevant for neutralization since exchange (Roben et al., 1994; Beidler et al., 1988). For AD-1-binding
antibodies, we originally observed a correlation betweenof the Fc portion from murine IgG2b and IgG3 to human
IgG1 did not result in a significant alteration in neutraliza- avidity and neutralization capacity with immunoglobulins
belonging to one recognition group. The data obtainedtion capacity. This includes potential cooperativity medi-
ated through murine IgG3 Fc portions (Fulpius et al., with chimeric antibodies confirmed this correlation for
immunoglobulins of groups A and C. Chimerization of1993; Greenspan and Cooper, 1993; Cooper et al., 1991).
In contrast, antibody 27-287 showed a significant in- murine antibody 27-287, which belongs to group B,
showed different results. The avidity of the chimeric 27-crease in neutralization capacity after exchange of the Fc
portion. Since all neutralization experiments were carried 287hu was drastically reduced, while its neutralizing ac-
tivity was increased. It can be speculated that immuno-out without complement, there are at least two possible
explanations. globulins binding to different substructures within AD-1
mediate neutralization via mechanisms which are depen-
dent or independent of the avidity of the respective anti-Steric effects mediated by the entire Fc portion
body. While group A-binding antibodies have a strong
correlation between avidity and neutralizing capacity,The results with the point mutations in AD-1 clearly
show that the three antibodies bind to different substruc- group B-binding immunoglobulins do not. An alternative
explanation could be that antibodies 27-287 and ITC33tures of AD-1. This probably results in a different orienta-
tion of the Fc portions in the three-dimensional space. do actually belong to two different recognition groups
which we were not able to distinguish with the availableExchange of the murine Fc part against the human IgG1
portion could lead to steric effects which affect events set of mutants.
What could be the consequences of these complexsuch as adsorption or penetration. Combined with the
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